First National Daily eMedical Newspaper of India
Nobody Reports News Better Than Us  
Editorial (Dr SS Agarwal, Dr K K Aggarwal)
To Read the full story on emedinexus.com, or download our Android app or iOS app
9th  December 2016
Alpha-1-blocker therapy in benign prostate hyperplasia
 
Drug treatment can reduce symptoms from benign prostatic hyperplasia.

A meta-analysis by the Agency for Healthcare Research and Quality (AHRQ) compared drugs or combinations of drugs developed in the past 10 years for treatment of BPH with monotherapy using older drugs.
 
Treatment with a newer alpha-1-blocker (AB) (silodosin), a combination of an anticholinergic drug (fesoterodine, tolterodine, or solifenacin) with an AB, or a phosphodiesterase type 5 (PDE-5) inhibitor (tadalafil) resulted in similar short-term symptom relief but a greater risk of adverse effects compared with treatment with an older AB (primarily tamsulosin).
To Read More or Comment, Click Here
Top News
Practice Updates
eMedi Humor
Medicolegal Corner
eMedi Quiz

1.     RLS also occurs at rest
2.     RLS is predominantly in the evening or at night
3.     RLS is sometimes painful.
4.     All of the above
Webcasts 

Lifestyle Updates
 
Inspirational Story 1: Live and Work
Inspirational Story 2: A Most Important Lesson
Press Release
Sleep apnea can put you at risk of heart disease
 
Up to 83% of people with heart disease also have sleep apnea.
Sleep deprivation is also linked to a higher risk of heart disease.
 
New Delhi, Dec 08, 2016: Sleep apnea is a condition characterized by frequent pauses in breathing leading to uninterrupted sleep. A person suffering from severe sleep apnea may experience pauses in breathing five to 30 times per hour or more during sleep.

One in five adults suffers from at least mild case of sleep apnea, and it tends to affect more men than women. The most common type of sleep apnea is obstructive sleep apnea in which weight on the upper chest and neck contributes to blocking the flow of air leading to frequent wakefulness.
To Read More or Comment, Click Here
IMA Updates